You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The cancer therapy developer has asked a US federal court to declare that its Illuminox platform does not infringe Illumina's trademarks.
Illumina had argued that Complete Genomics' patent covering two-color sequencing-by-synthesis chemistry was obvious, but the US PTAB disagreed.
The Broad Institute called UC's new legal strategy "deeply unfortunate" and called on the university to "move beyond litigation."
As MPEG LA tries to complete its larger CRISPR IP patent pool, smaller license agreements continue and a mini-pool has emerged between key players.
The process challenges claims made in certain UC Berkeley patents on the use of CRISPR-Cas9 to edit eukaryotic genomes.
The Patent Trial and Appeal Board has denied Foundation Medicine's request for Inter Partes review.
The firm's CEO Kevin Ness said confirmation of MAD7's editing activity in human HEK293T cells shows the potential for Inscripta's technology.
Reuters reports that the panel hearing the CRISPR gene editing patent case appears split.
The Broad Institute also announced announced a setback in proceedings over a CRISPR patent application filed in Europe.
Michelle Lee, the director of the United States Patent and Trademark Office, has resigned, IP Watchdog reports.
Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.
Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.
The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.
This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.